Syed Zafar, MD
Medical Oncology · Fort Myers, FLNPI 1811187909
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,841 of the $76,460 with a category attached, or 65.2%. It is spread thinly across 60 manufacturers, the largest accounting for just 11.5%. Reporting peaked in 2022 at $21,599 and has fallen 60.0% since, to $8,634 in 2025. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 642 payments — averaging $119.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$9K
- Seagen Inc.$9K
- Johnson & Johnson$8K
- E.r. Squibb & Sons, L.L.C.$7K
- GSK$6K
- Novartis$5K
- plus $33K from 54 others
Across 852 payments — averaging $4554.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beigene, Ltd.$2.2M
- Epizyme, Inc.$376K
- Mirati Therapeutics, Inc.$200K
- Astrazeneca UK Limited$193K
- TG Therapeutics, Inc.$179K
- GSK$154K
- plus $540K from 10 others
What the payments were for
- Consulting fees$49,84165%
- Speaking & faculty fees$8,01010%
- Travel & lodging$6,4928%
- Food & beverage$11,83915%
- Education$2780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,460 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 87 | $1,404,646 |
| JakafiRuxolitinib Phosphate | 67 | $1,150,655 |
| XtandiEnzalutamide | 62 | $866,035 |
| PomalystPomalidomide | 36 | $795,491 |
| TagrissoOsimertinib Mesylate | 27 | $425,947 |
| VonjoPacritinib Citrate | 13 | $340,869 |
| CabometyxCabozantinib S-Malate | 13 | $297,685 |
| IbrancePalbociclib | 20 | $297,198 |
| VerzenioAbemaciclib | 18 | $282,197 |
| LenvimaLenvatinib Mesylate | 13 | $279,671 |
| LumakrasSotorasib | 11 | $233,446 |
| CalquenceAcalabrutinib Maleate | 16 | $229,218 |
| NinlaroIxazomib Citrate | 18 | $222,367 |
| BrukinsaZanubrutinib | 13 | $187,924 |
| ImbruvicaIbrutinib | 12 | $166,591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $3,300 | $1,404,64687 claims |
| Incyte CorporationJakafi | $150 | $1,150,65567 claims |
| Astellas Pharma US IncXtandi | $126 | $866,03562 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $7,066 | $795,49136 claims |
| AstraZenecaTagrisso, Calquence | $8,812 | $655,16543 claims |
| PfizerIbrance, Eliquis | $636 | $365,306118 claims |
| Exelixis Inc.Cabometyx | $173 | $297,68513 claims |
| Lilly USA, LLCVerzenio | $119 | $282,19718 claims |
| Eisai Inc.Lenvima | $26 | $279,67113 claims |
| AmgenLumakras | $105 | $233,44611 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $186 | $222,36718 claims |
| Beigene USA, Inc.Brukinsa | $4,063 | $187,92413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Fort Myers
- Lowell HartFort Myers$257K
- Neil LoveMiami$5.6M
- Mahdi TahaBoca Raton$1.7M
- Raji ShameemOrlando$1.3M
- Mohammad JahanzebBoca Raton$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.